TapewireFind a company

person · Reporting owner

Saxonov Serge

Disclosed activity across 1 company

Tapewire entity
2173
SEC CIK
0001786720

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
10x Genomics, Inc.TXG · Entity 2172Director · Chief Executive OfficerSeptember 22, 2026September 24, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

10x Genomics, Inc.

Report date September 22, 2026 · Filed September 24, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeDirect1,050,249 Ending reported balance After 2026-09-22 transaction · row 5
5 source rows · reconciled sequence

Row 1 · 2026-09-22 · Sale · Disposed 1,000 · Balance 1,074,249

F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.

F2: This transaction was executed in multiple trades at prices ranging from $77.75 to $78.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Row 2 · 2026-09-22 · Sale · Disposed 2,000 · Balance 1,072,249

F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.

F3: This transaction was executed in multiple trades at prices ranging from $79.11 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Row 3 · 2026-09-22 · Sale · Disposed 9,300 · Balance 1,062,949

F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.

F4: This transaction was executed in multiple trades at prices ranging from $80.28 to $81.27, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Row 4 · 2026-09-22 · Sale · Disposed 9,900 · Balance 1,053,049

F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.

F5: This transaction was executed in multiple trades at prices ranging from $81.28 to $82.25 inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Row 5 · 2026-09-22 · Sale · Disposed 2,800 · Balance 1,050,249

F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.

F6: This transaction was executed in multiple trades at prices ranging from $82.28 to $82.53, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Class A Common StockSEC Table I · non-derivativeIndirectSee footnote27 Reported balance Holding disclosure · report date 2026-09-22 · row 6 Holding and transaction disclosures are not merged.
1 source row

Row 6 · Balance 27

F7: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

Class A Common StockSEC Table I · non-derivativeIndirectSee footnote213,250 Reported balance Holding disclosure · report date 2026-09-22 · row 7 Holding and transaction disclosures are not merged.
1 source row

Row 7 · Balance 213,250

F8: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

Class A Common StockSEC Table I · non-derivativeIndirectSee footnote71,644 Reported balance Holding disclosure · report date 2026-09-22 · row 8 Holding and transaction disclosures are not merged.
1 source row

Row 8 · Balance 71,644

F9: The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

Filing footnotes · ownership attribution and instrument terms

F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.

F2: This transaction was executed in multiple trades at prices ranging from $77.75 to $78.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: This transaction was executed in multiple trades at prices ranging from $79.11 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $80.28 to $81.27, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: This transaction was executed in multiple trades at prices ranging from $81.28 to $82.25 inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F6: This transaction was executed in multiple trades at prices ranging from $82.28 to $82.53, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F7: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

F8: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

F9: The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 06, 2020 Filed Mar 10, 2020 01:46 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 1,098 $64.91 $71,273.49
Disclosure

SEC source: 0001209191-20-017554 · doc4.xml · nonDerivative · entry 5

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 941,301

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $64.40 to $65.24. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
March 06, 2020 Filed Mar 10, 2020 01:46 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 3,767 $63.91 $240,761.02
Disclosure

SEC source: 0001209191-20-017554 · doc4.xml · nonDerivative · entry 4

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 942,399

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $63.405 to $64.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
March 06, 2020 Filed Mar 10, 2020 01:46 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 1,848 $62.91 $116,262.48
Disclosure

SEC source: 0001209191-20-017554 · doc4.xml · nonDerivative · entry 3

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 946,166

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $62.39 to $63.25. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
March 06, 2020 Filed Mar 10, 2020 01:46 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 1,667 $1.20 $2,000.40
Disclosure

SEC source: 0001209191-20-017554 · doc4.xml · nonDerivative · entry 2

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 948,014

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
March 06, 2020 Filed Mar 10, 2020 01:46 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 8,333 $1.07 $8,916.31
Disclosure

SEC source: 0001209191-20-017554 · doc4.xml · nonDerivative · entry 1

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 946,347

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
January 10, 2020 Filed Jan 14, 2020 21:04 UTC 10x Genomics, Inc. TXG · Entity 2172 GrantStock Option (right to buy) · Derivative 150,000 $0.00 Strike: $1.20 $0.00
Disclosure

SEC source: 0001209191-20-003280 · doc4.xml · derivative · entry 1

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Class A Common Stock · 150,000 shares

Expires 2027-10-18

F1 · derivative.exercise_date: On January 10, 2020, the Compensation Committee of the Board of Directors of the Issuer determined that certain performance targets had been achieved pertaining to a 150,000 share option granted to the Reporting Person on October 18, 2017. The option vests as to one-thirty-sixth of the shares on January 1, 2020 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
October 14, 2019 Filed Oct 16, 2019 01:19 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 3,037 $0.00 Strike: $11.48 $0.00
Disclosure

SEC source: 0001209191-19-053229 · doc4.xml · derivative · entry 10

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,563

Underlying: Class A Common Stock · 3,037 shares

Expires 2029-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This option, originally for 145,786 shares, of which 18,223 have been exercised, vested as to one forty-eighth of the shares on May 1, 2019, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
October 14, 2019 Filed Oct 16, 2019 01:19 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 5,208 $0.00 Strike: $5.04 $0.00
Disclosure

SEC source: 0001209191-19-053229 · doc4.xml · derivative · entry 9

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 182,292

Underlying: Class A Common Stock · 5,208 shares

Expires 2028-11-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option, originally for 250,000 shares, of which 67,708 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
October 14, 2019 Filed Oct 16, 2019 01:19 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 4,167 $0.00 Strike: $1.20 $0.00
Disclosure

SEC source: 0001209191-19-053229 · doc4.xml · derivative · entry 8

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,500

Underlying: Class A Common Stock · 4,167 shares

Expires 2027-10-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option, originally for 150,000 shares, of which 37,500 have been exercised, vested as to one thirty-sixth of the shares on January 1, 2019, and one thirty-sixth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date

Read SEC document
October 14, 2019 Filed Oct 16, 2019 01:19 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 6,250 $0.00 Strike: $1.20 $0.00
Disclosure

SEC source: 0001209191-19-053229 · doc4.xml · derivative · entry 7

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 143,750

Underlying: Class A Common Stock · 6,250 shares

Expires 2027-10-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option, originally for 300,000 shares, of which 156,250 have been exercised, vested as to one forty-eighth of the shares on October 1, 2017, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
October 14, 2019 Filed Oct 16, 2019 01:19 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 4,167 $0.00 Strike: $1.07 $0.00
Disclosure

SEC source: 0001209191-19-053229 · doc4.xml · derivative · entry 6

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,667

Underlying: Class A Common Stock · 4,167 shares

Expires 2026-11-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option, originally for 200,000 shares, of which 158,333 have been exercised, vested as to one-fourth of the shares on August 1, 2017, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
October 14, 2019 Filed Oct 16, 2019 01:19 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 3,037 $11.48 $34,864.76
Disclosure

SEC source: 0001209191-19-053229 · doc4.xml · nonDerivative · entry 5

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 938,014

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 14, 2019 Filed Oct 16, 2019 01:19 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 5,208 $5.04 $26,248.32
Disclosure

SEC source: 0001209191-19-053229 · doc4.xml · nonDerivative · entry 4

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 934,977

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 14, 2019 Filed Oct 16, 2019 01:19 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 4,167 $1.20 $5,000.40
Disclosure

SEC source: 0001209191-19-053229 · doc4.xml · nonDerivative · entry 3

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 929,769

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 14, 2019 Filed Oct 16, 2019 01:19 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 6,250 $1.20 $7,500.00
Disclosure

SEC source: 0001209191-19-053229 · doc4.xml · nonDerivative · entry 2

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 925,602

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 14, 2019 Filed Oct 16, 2019 01:19 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 4,167 $1.07 $4,458.69
Disclosure

SEC source: 0001209191-19-053229 · doc4.xml · nonDerivative · entry 1

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 919,352

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 16, 2019 Filed Sep 16, 2019 20:15 UTC 10x Genomics, Inc. TXG · Entity 2172 OtherStock Option (right to buy) · Derivative 130,600 $0.00 Strike: $11.48 $0.00
Disclosure

SEC source: 0000899243-19-023629 · doc4.xml · derivative · entry 18

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,600

Underlying: Class A Common Stock · 130,600 shares

Expires 2029-05-10

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

F9 · derivative.exercise_date: This option, originally for 145,786 shares, of which 15,186 have been exercised, vested as to one forty-eighth of the shares on May 1, 2019, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

Read SEC document
September 16, 2019 Filed Sep 16, 2019 20:15 UTC 10x Genomics, Inc. TXG · Entity 2172 OtherStock Option (right to buy) · Derivative 130,600 $0.00 Strike: $11.48 $0.00
Disclosure

SEC source: 0000899243-19-023629 · doc4.xml · derivative · entry 17

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class B Common Stock · 130,600 shares

Expires 2029-05-10

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

F9 · derivative.exercise_date: This option, originally for 145,786 shares, of which 15,186 have been exercised, vested as to one forty-eighth of the shares on May 1, 2019, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

Read SEC document
September 16, 2019 Filed Sep 16, 2019 20:15 UTC 10x Genomics, Inc. TXG · Entity 2172 OtherStock Option (right to buy) · Derivative 187,500 $0.00 Strike: $5.04 $0.00
Disclosure

SEC source: 0000899243-19-023629 · doc4.xml · derivative · entry 16

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,500

Underlying: Class A Common Stock · 187,500 shares

Expires 2028-11-02

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

F8 · derivative.exercise_date: This option, originally for 250,000 shares, of which 62,500 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

Read SEC document
September 16, 2019 Filed Sep 16, 2019 20:15 UTC 10x Genomics, Inc. TXG · Entity 2172 OtherStock Option (right to buy) · Derivative 187,500 $0.00 Strike: $5.04 $0.00
Disclosure

SEC source: 0000899243-19-023629 · doc4.xml · derivative · entry 15

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class B Common Stock · 187,500 shares

Expires 2028-11-02

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

F8 · derivative.exercise_date: This option, originally for 250,000 shares, of which 62,500 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

Read SEC document
September 16, 2019 Filed Sep 16, 2019 20:15 UTC 10x Genomics, Inc. TXG · Entity 2172 OtherStock Option (right to buy) · Derivative 116,667 $0.00 Strike: $1.20 $0.00
Disclosure

SEC source: 0000899243-19-023629 · doc4.xml · derivative · entry 14

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,667

Underlying: Class A Common Stock · 116,667 shares

Expires 2027-10-18

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

F7 · derivative.exercise_date: This option, originally for 150,000 shares, of which 33,333 have been exercised, vested as to one thirty-sixth of the shares on January 1, 2019, and one thirty-sixth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

Read SEC document
September 16, 2019 Filed Sep 16, 2019 20:15 UTC 10x Genomics, Inc. TXG · Entity 2172 OtherStock Option (right to buy) · Derivative 116,667 $0.00 Strike: $1.20 $0.00
Disclosure

SEC source: 0000899243-19-023629 · doc4.xml · derivative · entry 13

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class B Common Stock · 116,667 shares

Expires 2027-10-18

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

F7 · derivative.exercise_date: This option, originally for 150,000 shares, of which 33,333 have been exercised, vested as to one thirty-sixth of the shares on January 1, 2019, and one thirty-sixth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

Read SEC document
September 16, 2019 Filed Sep 16, 2019 20:15 UTC 10x Genomics, Inc. TXG · Entity 2172 OtherStock Option (right to buy) · Derivative 150,000 $0.00 Strike: $1.20 $0.00
Disclosure

SEC source: 0000899243-19-023629 · doc4.xml · derivative · entry 12

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Class A Common Stock · 150,000 shares

Expires 2027-10-18

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

F6 · derivative.exercise_date: This option, originally for 300,000 shares, of which 150,000 have been exercised, vested as to one forty-eighth of the shares on October 1, 2017, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

Read SEC document
September 16, 2019 Filed Sep 16, 2019 20:15 UTC 10x Genomics, Inc. TXG · Entity 2172 OtherStock Option (right to buy) · Derivative 150,000 $0.00 Strike: $1.20 $0.00
Disclosure

SEC source: 0000899243-19-023629 · doc4.xml · derivative · entry 11

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class B Common Stock · 150,000 shares

Expires 2027-10-18

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

F6 · derivative.exercise_date: This option, originally for 300,000 shares, of which 150,000 have been exercised, vested as to one forty-eighth of the shares on October 1, 2017, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

Read SEC document
September 16, 2019 Filed Sep 16, 2019 20:15 UTC 10x Genomics, Inc. TXG · Entity 2172 OtherStock Option (right to buy) · Derivative 45,834 $0.00 Strike: $1.07 $0.00
Disclosure

SEC source: 0000899243-19-023629 · doc4.xml · derivative · entry 10

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,834

Underlying: Class A Common Stock · 45,834 shares

Expires 2026-11-18

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

F5 · derivative.exercise_date: This option, originally for 200,000 shares, of which 154,166 have been exercised, vested as to one-fourth of the shares on August 1, 2017, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

Read SEC document
September 16, 2019 Filed Sep 16, 2019 20:15 UTC 10x Genomics, Inc. TXG · Entity 2172 OtherStock Option (right to buy) · Derivative 45,834 $0.00 Strike: $1.07 $0.00
Disclosure

SEC source: 0000899243-19-023629 · doc4.xml · derivative · entry 9

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class B Common Stock · 45,834 shares

Expires 2026-11-18

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

F5 · derivative.exercise_date: This option, originally for 200,000 shares, of which 154,166 have been exercised, vested as to one-fourth of the shares on August 1, 2017, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

Read SEC document
September 16, 2019 Filed Sep 16, 2019 20:15 UTC 10x Genomics, Inc. TXG · Entity 2172 OtherClass B Common Stock · Derivative 1,750,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-023629 · doc4.xml · derivative · entry 8

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,750,000

Underlying: Class A Common Stock · 1,750,000 shares

Expires not disclosed

F3 · security: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F3 · derivative.exercise_price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F3 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F3 · derivative.exercise_date: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F3 · derivative.expiration_date: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F3 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F4 · ownership.nature: 250,000 shares are held by each of Polaris 2018 Irrevocable Trust, Antares 2018 Irrevocable Trust, Arcturus 2018 Irrevocable Trust, FLY 2018 Irrevocable Trust, LY 2018 Irrevocable Trust, MS 2018 Irrevocable Trust and NS 2018 Irrevocable Trust, of which the Reporting Person is the sole trustee.

Read SEC document
September 16, 2019 Filed Sep 16, 2019 20:15 UTC 10x Genomics, Inc. TXG · Entity 2172 OtherClass A Common Stock · Derivative 1,750,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-023629 · doc4.xml · derivative · entry 7

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Class B Common Stock · 1,750,000 shares

Expires not disclosed

F3 · security: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F3 · derivative.exercise_price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F3 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F3 · derivative.exercise_date: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F3 · derivative.expiration_date: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F3 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F4 · ownership.nature: 250,000 shares are held by each of Polaris 2018 Irrevocable Trust, Antares 2018 Irrevocable Trust, Arcturus 2018 Irrevocable Trust, FLY 2018 Irrevocable Trust, LY 2018 Irrevocable Trust, MS 2018 Irrevocable Trust and NS 2018 Irrevocable Trust, of which the Reporting Person is the sole trustee.

Read SEC document
September 16, 2019 Filed Sep 16, 2019 20:15 UTC 10x Genomics, Inc. TXG · Entity 2172 OtherClass B Common Stock · Derivative 1,250,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-023629 · doc4.xml · derivative · entry 6

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,250,000

Underlying: Class A Common Stock · 1,250,000 shares

Expires not disclosed

F3 · security: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F3 · derivative.exercise_price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F3 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F3 · derivative.exercise_date: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F3 · derivative.expiration_date: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F3 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

Read SEC document
September 16, 2019 Filed Sep 16, 2019 20:15 UTC 10x Genomics, Inc. TXG · Entity 2172 OtherClass A Common Stock · Derivative 1,250,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-023629 · doc4.xml · derivative · entry 5

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class B Common Stock · 1,250,000 shares

Expires not disclosed

F3 · security: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F3 · derivative.exercise_price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F3 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F3 · derivative.exercise_date: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F3 · derivative.expiration_date: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F3 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

Read SEC document
September 16, 2019 Filed Sep 16, 2019 20:15 UTC 10x Genomics, Inc. TXG · Entity 2172 ConversionClass B Common Stock · Derivative 31,865 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-023629 · doc4.xml · derivative · entry 4

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,865

Underlying: Class A Common Stock · 31,865 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: The Series A-1 Preferred Stock automatically converted into Class B Common Stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F2 · derivative.exercise_price: The Series A-1 Preferred Stock automatically converted into Class B Common Stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F2 · derivative.exercise_date: The Series A-1 Preferred Stock automatically converted into Class B Common Stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F2 · derivative.expiration_date: The Series A-1 Preferred Stock automatically converted into Class B Common Stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F2 · derivative.underlying: The Series A-1 Preferred Stock automatically converted into Class B Common Stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

Read SEC document
September 16, 2019 Filed Sep 16, 2019 20:15 UTC 10x Genomics, Inc. TXG · Entity 2172 ConversionSeries A-1 Preferred Stock · Derivative 31,865 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-023629 · doc4.xml · derivative · entry 3

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class B Common Stock · 31,865 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: The Series A-1 Preferred Stock automatically converted into Class B Common Stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F2 · derivative.exercise_price: The Series A-1 Preferred Stock automatically converted into Class B Common Stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F2 · derivative.exercise_date: The Series A-1 Preferred Stock automatically converted into Class B Common Stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F2 · derivative.expiration_date: The Series A-1 Preferred Stock automatically converted into Class B Common Stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F2 · derivative.underlying: The Series A-1 Preferred Stock automatically converted into Class B Common Stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

Read SEC document
September 16, 2019 Filed Sep 16, 2019 20:15 UTC 10x Genomics, Inc. TXG · Entity 2172 OtherClass A Common Stock 915,185 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-023629 · doc4.xml · nonDerivative · entry 2

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 915,185

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

F1 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

Read SEC document
September 16, 2019 Filed Sep 16, 2019 20:15 UTC 10x Genomics, Inc. TXG · Entity 2172 OtherClass B Common Stock 915,185 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-023629 · doc4.xml · nonDerivative · entry 1

Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

F1 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.